EVAXION BIOTECH AS

NASDAQ: EVAX (Evaxion A/S)

Kemas kini terakhir: 27 Nov, 12:40AM

5.65

0.25 (4.63%)

Penutupan Terdahulu 5.40
Buka 5.19
Jumlah Dagangan 37,884
Purata Dagangan (3B) 1,625,057
Modal Pasaran 47,122,216
Harga / Jualan (P/S) 3.19
Harga / Buku (P/B) 4.81
Julat 52 Minggu
1.20 (-78%) — 12.15 (115%)
Tarikh Pendapatan 12 Aug 2025 - 18 Aug 2025
Margin Operasi (TTM) -431.34%
EPS Cair (TTM) -12.00
Pertumbuhan Hasil Suku Tahunan (YOY) 67.10%
Jumlah Hutang/Ekuiti (D/E MRQ) 837.11%
Nisbah Semasa (MRQ) 2.01
Aliran Tunai Operasi (OCF TTM) -12.94 M
Aliran Tunai Bebas Leveraj (LFCF TTM) -11.59 M
Pulangan Atas Aset (ROA TTM) -37.07%
Pulangan Atas Ekuiti (ROE TTM) -206.44%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Biotechnology (US) Bercampur Bercampur
Biotechnology (Global) Bercampur Bercampur
Stok Evaxion A/S Menurun Menurun

AISkor Stockmoo

-0.4
Konsensus Penganalisis 1.0
Aktiviti Orang Dalam NA
Volatiliti Harga -4.5
Purata Bergerak Teknikal 2.5
Osilator Teknikal -0.5
Purata -0.38

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
EVAX 47 M - - 4.81
BNTX 23 B - - 1.07
LEGN 4 B - - 4.36
GPCR 4 B - - 5.50
DNTH 2 B - - 3.47
ALMS 1 B - - 3.29

Evaxion AS is a techBio company based on its AI platform, AI-Immunology. Evaxion’s proprietary and scalable AI prediction models harness the power of artificial intelligence to decode the human immune system and develop novel immunotherapies for cancer, bacterial diseases, and viral infections. Evaxion has developed a clinical-stage oncology pipeline of novel personalised vaccines and a preclinical infectious disease pipeline in bacterial and viral diseases with high unmet medical needs. The group is committed to transforming patients’ lives by providing innovative and targeted treatment options.

Sektor Healthcare
Industri Biotechnology
% Dimiliki oleh Orang Dalam 23.07%
% Dimiliki oleh Institusi 7.09%

Pemilikan

Nama Tarikh Syer Dipegang
Beacon Capital Management, Llc 30 Sep 2025 0
Julat 52 Minggu
1.20 (-78%) — 12.15 (115%)
Julat Harga Sasaran
10.00 (76%) — 16.00 (183%)
Tinggi 16.00 (HC Wainwright & Co., 183.19%) Beli
Median 11.00 (94.69%)
Rendah 10.00 (Edward Jones, 76.99%) Beli
Purata 12.33 (118.23%)
Jumlah 3 Beli
Harga Purata @ Panggilan 6.65
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Edward Jones 30 Oct 2025 10.00 (76.99%) Beli 5.76
HC Wainwright & Co. 20 Oct 2025 16.00 (183.19%) Beli 7.09
25 Sep 2025 16.00 (183.19%) Beli 4.53
Lake Street 20 Oct 2025 11.00 (94.69%) Beli 7.09

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
06 Dec 2025 Pengumuman Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting
06 Dec 2025 Pengumuman Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting
20 Nov 2025 Pengumuman Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1
20 Nov 2025 Pengumuman Evaxion announces positive data for lead antigens in cytomegalovirus (CMV) vaccine program EVX-V1
12 Nov 2025 Pengumuman Evaxion announce 2026 financial calendar
12 Nov 2025 Pengumuman Evaxion announce 2026 financial calendar
07 Nov 2025 Pengumuman Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
07 Nov 2025 Pengumuman Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01
06 Nov 2025 Pengumuman Evaxion announces business update and third quarter 2025 financial results
06 Nov 2025 Pengumuman Evaxion announces business update and third quarter 2025 financial results
03 Nov 2025 Pengumuman Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate
03 Nov 2025 Pengumuman Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate
31 Oct 2025 Pengumuman Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
31 Oct 2025 Pengumuman Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
31 Oct 2025 Pengumuman Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025
30 Oct 2025 Pengumuman Evaxion raises $7.2 million, extending cash runway to second half of 2027
30 Oct 2025 Pengumuman Evaxion raises $7.2 million, extending cash runway to second half of 2027
27 Oct 2025 Pengumuman Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer
27 Oct 2025 Pengumuman Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer
17 Oct 2025 Pengumuman Natural Killer Cell Therapies Lead $254B Immunotherapy Market Transformation
17 Oct 2025 Pengumuman Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01
17 Oct 2025 Pengumuman Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01
13 Oct 2025 Pengumuman Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
13 Oct 2025 Pengumuman Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025
08 Oct 2025 Pengumuman Evaxion expands AI-Immunology™ platform with automated vaccine design module
08 Oct 2025 Pengumuman Evaxion expands AI-Immunology™ platform with automated vaccine design module
03 Oct 2025 Pengumuman Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting
03 Oct 2025 Pengumuman Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting
25 Sep 2025 Pengumuman Evaxion out-licenses vaccine candidate EVX-B3 to MSD
25 Sep 2025 Pengumuman Evaxion out-licenses vaccine candidate EVX-B3 to MSD
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2025 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda